# BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct07755904` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07755904](<https://clinicaltrials.gov/study/NCT07755904>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07755904

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.

## Technical summary

Registry record NCT07755904. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-02 (actual); primary completion 2028-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 210 participants (planned count; ClinicalTrials.gov record NCT07755904, source copy `cardio:ctgov-nct07755904-2026-11-10`, retrieved 2026-11-18)
- Started: 2026-09-02 (actual) (ClinicalTrials.gov record NCT07755904, source copy `cardio:ctgov-nct07755904-2026-11-10`, retrieved 2026-11-18)
- Primary completion: 2028-10 (anticipated) (ClinicalTrials.gov record NCT07755904, source copy `cardio:ctgov-nct07755904-2026-11-10`, retrieved 2026-11-18)
- Completion: 2028-11 (anticipated) (ClinicalTrials.gov record NCT07755904, source copy `cardio:ctgov-nct07755904-2026-11-10`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07755904, source copy `cardio:ctgov-nct07755904-2026-11-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07755904-2026-11-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Acronym: LIONHEART-HCM
- Condition: Cardiomyopathy, Hypertrophic Obstructive
- Intervention (Drug): BHB-1893
- Intervention (Drug): Metoprolol
- Lead sponsor: Braveheart Bio, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry intervention name matches this record: Metoprolol (`cardio:metoprolol`)

## Provenance

Content hash: 1f419ac343ecd0a96e59d201f32aa6b26280018b159831628566657cbcb789f4
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
